ProCE Banner Activity

CCO Think Tank on Emerging HER2-Targeted ADCs: Genitourinary Malignancies


Slides from Elizabeth Plimack, MD, covering the recent developments in HER2 testing, clinical trial results for anti-HER2 antibody-drug conjugate (ADC) therapy, and current strategies on managing the safety profile of ADCs.

Released: March 22, 2024

Expiration: March 21, 2025



Elizabeth R. Plimack

Elizabeth R. Plimack, MD, MS, FASCO

Deputy Director
Professor of Medical Oncology
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.


Daiichi Sankyo, Inc.